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ABSTRACT 
The sustainability of health systems is being challenged by the increasing demand of financial 
resources to support pharmacological and diagnostic innovation. Therefore, to ensure long-term 
universal access to care, an investment shift towards health promotion and disease prevention 
is required, along with a more efficient management of the scarce financial resources. 
Oncologic diseases are among the main causes of morbidity and mortality, particularly in high-
income countries, accounting for an expenditure of 1.5% of the world’s gross domestic product. 
However, the number of cancer cases can be reduced substantially through the implementation 
of prevention and control strategies, such as lifestyle changes, vaccination and screening. 
Cervical cancer is one of the most preventable oncologic diseases, both through well-organized 
screening programs and human papillomavirus (HPV) vaccination; nevertheless, it remains the 
fourth most commonly diagnosed cancer in women globally. Although HPV vaccination may be 
the most relevant intervention to prevent cervical cancer in the future, organized screening will 
remain necessary, at least for nonvaccinated women. The simultaneous implementation of 
these two strategies may compromise the financial sustainability of organized screening, since 
HPV vaccination will increase the number of women who need to be screened to prevent a 
cancer death, while the costs with quality assurance and monitoring of organized screening will 
remain constant. Additionally, population adherence to organized screening is often low, 
contributing to the inefficient use of the scarce financial resources. Therefore, organized cervical 
cancer screening needs to be reshaped to ensure its cost-effectiveness, namely through the 
implementation of strategies that increase women’s participation at an affordable price. This 
may be achieved through the combination of automated and low-cost invitations to cervical 
cancer screening applied to the entire population, with the remaining non-adherent women 
receiving more customized and costly interventions. 
 
This thesis intends to test the effectiveness and cost-effectiveness of an invitation strategy, with 
an increasing level of customization and cost, to increase adherence to organized cervical cancer 
screening, in comparison with a written letter (i.e., the standard of care). The intervention tested 
includes automated text messages/phone calls/reminders (step 1), manual phone calls 
performed by clinical secretaries (step 2) and face-to-face interviews conducted by family 
doctors (step 3), applied sequentially to women remaining non-adherent after each step. 
The following paragraphs describe the specific objectives defined for this thesis, along with the 
corresponding methods and main results: 
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1) To test the superiority of an invitation strategy based on step 1, steps 1+2 and steps 
1+2+3 in relation to the standard of care. 
 
This was accomplished through a multicentre, parallel, population-based randomized controlled 
trial (Stepwise Strategy to improve Cervical Cancer Screening Adherence - SCAN trial), including 
women eligible for cervical cancer screening, aged 25 to 49 years, registered in the Porto 
Ocidental or Marão e Douro Norte Health Care Areas (Portugal), with an available mobile phone 
number. In the intervention group, women were invited through a stepwise strategy, based on 
steps 1 to 3, which were applied sequentially to women remaining non-adherent after each step. 
Women in the control group were invited through a written letter. The primary outcome was 
the proportion of women screened after step 1 (assessed 45 days after the initial invitation), 
steps 1+2 (assessed 90 days after the initial invitation) and steps 1+2+3 (assessed 150 days after 
the initial invitation). 
Adherence to cervical cancer screening was significantly higher among women assigned to the 
intervention, after step 1 (39.9% vs. 25.7%, p<0.001), steps 1+2 (48.6% vs. 30.7%, p<0.001) and 
steps 1+2+3 (51.2% vs. 34.0%, p<0.001).  
To promote the diffusion of this knowledge, the results of step 1 intervention were 
communicated to the primary health care units and professionals involved in SCAN trial through 
reports customized according to the primary health care unit characteristics and interests.  
2) To compare the cost-effectiveness of an invitation based on step 1, steps 1+2 and steps 
1+2+3 with the standard of care strategy. 
 
The second objective was addressed through a decision tree model, which compared the cost-
effectiveness of four competing invitation strategies to cervical cancer screening: (a) a written 
letter; (b) step 1 invitation strategy; (c) steps 1+2 invitation strategies; (d) steps 1+2+3 invitation 
strategies. The main outcome was the cost per quality-adjusted life year (QALY) measured over 
a five-year time horizon. Adherence to cervical cancer screening after each of the competing 
interventions was obtained from the SCAN trial and the corresponding QALYs were estimated 
based on previous studies. Costs were estimated from the provider and societal perspective 
using patient-level data from the SCAN trial, or if not available, from portuguese data sources or 
the international literature. The benefits and costs of the invitation strategies were used to 
compute incremental cost-effectiveness ratios (ICER), which were compared to a willingness-to-
pay threshold of €22398 per QALY (i.e., one time the Portuguese gross domestic product per 
capita). The strategy with the highest ICER just below the threshold was considered the most 
cost-effective option.  
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This study showed that an invitation to cervical cancer screening based on steps 1+2 was a very 
cost-effective strategy (ICER of €4286 and €9394 from the provider and societal perspective, 
respectively) surpassing the standard of care, which was strongly dominated (i.e., less effective 
and more costly than other strategies), as well as the interventions based on step 1 or steps 
1+2+3.  
In conclusion, the results of this thesis show that an invitation strategy with an increasing level 
of customization, based on automated text messages/phone calls/reminders, manual phone 
calls and face-to-face interviews or combinations of its’ components increased the adherence 
to organized cervical cancer screening, in comparison with the standard of care. Further, it 
supports the implementation of automated text messages/phone calls/reminders and manual 
phone calls as the new standard of care invitation to cervical cancer screening, under a 
willingness-to-pay threshold of one time the Portuguese gross domestic product per capita. 
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RESUMO 
A sustentabilidade dos sistemas de saúde encontra-se ameaçada pela necessidade crescente de 
recursos financeiros que suportem a implementação das necessárias inovações ao nível 
diagnóstico e farmacológico. Assim, para garantir que a longo prazo o acesso aos cuidados de 
saúde permanece universal, é necessário priorizar o investimento nas áreas de promoção da 
saúde e prevenção da doença, bem como promover uma gestão mais eficiente do escasso 
orçamento disponível.  
As doenças oncológicas são uma das principais causas de morbilidade e mortalidade, 
particularmente nos países de mais alto rendimento, sendo os gastos anuais necessários para o 
seu tratamento superiores a 1,5% do produto interno bruto mundial. No entanto, é possível 
reduzir de forma substancial o número de novos casos de cancro através da implementação de 
estratégias de prevenção e controlo, tais como alterações dos estilos de vida, vacinação e 
rastreio. O cancro do colo do útero é umas das doenças oncológicas mais preveníveis, seja 
através da administração da vacina do vírus do papiloma humano (HPV) ou do rastreio, apesar 
de permanecer como a quarta causa mais frequente de cancro nas mulheres, em todo o mundo. 
No futuro, é expectável que a vacina do HPV se torne a intervenção mais relevante em termos 
de prevenção do cancro do colo do útero, apesar de continuar a ser necessário a implementação 
de um rastreio organizado, pelo menos para as mulheres não vacinadas. Contudo, a 
implementação simultânea destas duas estratégias pode comprometer a sustentabilidade 
financeira dos programas de rastreio; a vacinação irá aumentar o número de mulheres a rastrear 
para prevenir uma morte por cancro do colo do útero, mantendo-se, no entanto, os custos com 
a monitorização e avaliação do rastreio organizado. Além disso, a adesão ao rastreio organizado 
é frequentemente baixa, contribuindo para a utilização ineficiente dos escassos recursos 
financeiros do sector da saúde. Desta forma, o rastreio organizado deve ser redesenhado de 
forma a garantir a sua custo-efetividade, nomeadamente através da implementação de 
estratégias de custo reduzido que aumentem a participação das mulheres elegíveis. Este 
objetivo poderá ser alcançado através da utilização de convites automáticos e de baixo custo 
remetidos para toda a população-alvo e, intervenções mais personalizadas e com maior custo 
de implementação, para as mulheres que não adiram ao rastreio após esta estratégia.  
 
Esta tese pretende testar a efetividade e custo-efetividade de uma estratégia de convite, com 
um grau crescente de personalização e custo, para aumentar a adesão ao rastreio organizado 
do cancro do colo do útero, em comparação com o procedimento de convite habitualmente 
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utilizado (i.e., carta remetida por correio). A estratégia testada inclui intervenções automáticas 
– mensagens de texto curtas (SMS), chamadas e lembretes (etapa 1), chamadas manuais 
realizadas por secretários clínicos (etapa 2), entrevistas presenciais efetuadas por médicos de 
família (etapa 3), aplicadas de forma sequencial às mulheres que não aderiram ao rastreio do 
cancro do colo do útero, após cada uma das etapas.  
Os parágrafos seguintes descrevem os objetivos específicos definidos para esta tese, bem como 
os respetivos métodos e principais resultados:  
 
1) Testar a superioridade de uma estratégia de convite para o rastreio do cancro do colo 
do útero, composta pelas intervenções da etapa 1, etapas 1+2 e etapas 1+2+3, em 
comparação com o método de convite habitual. 
 
Para responder a este objetivo foi implementado um estudo aleatorizado e controlado, paralelo, 
multicêntrico e de base populacional (Stepwise Strategy to improve Cervical Cancer Screening 
Adherence - SCAN trial), que incluiu mulheres elegíveis para rastreio do cancro do colo do útero, 
com idades compreendidas entre os 25 e os 49 anos, inscritas nos Agrupamentos de Centros de 
Saúde do Porto Ocidental ou Marão e Douro Norte, com um número de telefone móvel 
disponível. No grupo de intervenção, as utentes foram convidadas através de uma estratégia 
composta pelas etapas 1 a 3, aplicadas de forma sequencial às mulheres que não aderiram ao 
rastreio após a implementação da etapa anterior. As mulheres aleatorizadas para o grupo de 
controlo foram convidadas através de uma carta remetida por correio. Foi considerado como 
outcome primário do estudo a proporção de mulheres rastreadas, após a etapa 1 (avaliado 45 
dias após o convite inicial), etapas 1+2 (avaliado 90 dias após o convite inicial) e etapas 1+2+3 
(avaliado 150 dias após o convite inicial).  
A adesão ao rastreio do cancro do colo do útero foi significativamente superior nas mulheres 
aleatorizadas para o grupo de intervenção, após a etapa 1 (39,9% vs. 25,7%; p<0,001), etapas 
1+2 (48,6% vs. 30,7%; p<0,001) e etapas 1+2+3 (51,2% vs. 34,0%; p<0,001). 
De forma a promover a difusão do conhecimento gerado, os resultados da etapa 1 foram 
comunicados às unidades de cuidados de saúde primários envolvidas no estudo SCAN, através 
da utilização de relatórios personalizados de acordo com as suas características e interesses.  
 
2) Comparar a custo-efetividade de uma estratégia de convite para o rastreio do cancro do 
colo do útero, composta pelas intervenções da etapa 1, etapas 1+2 e etapas 1+2+3, com 
o método de convite habitual.  
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Realizou-se um estudo de avaliação económica, no qual foram utilizados modelos de árvore de 
decisão, para comparar a custo-efetividade de quatro estratégias de convite para rastreio do 
cancro do colo do útero: (a) carta remetida por correio; (b) intervenções da etapa 1; (c) 
intervenções das etapas 1+2; (d) intervenções das etapas 1+2+3. Foi considerado como outcome 
primário do estudo o custo por quality-adjusted life year (QALY), assumindo uma janela 
temporal de análise de cinco anos. A adesão ao rastreio do cancro do colo do útero, após a 
implementação de cada uma das estratégias de convite, foi obtida a partir do estudo SCAN e 
convertida em QALYs, de acordo com as orientações descritas na literatura. Os custos incluídos 
nos modelos económicos foram calculados na perspetiva do prestador e societal, considerando 
para o efeito custos obtidos do estudo SCAN, bem como fontes de informação nacionais e 
estudos internacionais. Os benefícios e custos de cada uma das estratégias de convite foram 
utilizados para calcular rácios de custo-efetividade (incremental cost-effectiveness ratios, 
designados ICER) e comparados com um valor de disponibilidade a pagar de 22398€ por cada 
QALY (i.e., o valor do produto interno bruto per capita de Portugal). A estratégia que apresentou 
o valor de ICER mais elevado, imediatamente abaixo do patamar de disponibilidade a pagar por 
QALY, foi considerada como a opção mais custo-efetiva.  
Este estudo mostrou que uma estratégia de convite para rastreio do cancro do colo do útero 
composta pelas etapas 1+2 foi altamente custo-efetiva, com valores de ICER de 4286€ e 9394€, 
na perspetiva societal e do prestador, respetivamente. Esta intervenção é mais custo-efetiva do 
que o procedimento de convite habitual, o qual foi fortemente dominado (i.e., estratégia menos 
efetiva e mais cara do que outra intervenção), mas também superior às intervenções compostas 
pela etapa 1 ou etapas 1+2+3.  
Em conclusão, os resultados desta tese mostraram que uma estratégia de convite com um grau 
crescente de personalização, baseada em intervenções automáticas (SMS, chamadas e 
lembretes), chamadas manuais e entrevistas presenciais ou combinações destes componentes, 
resultou em um aumento da adesão ao rastreio organizado do cancro do colo do útero, em 
comparação com o procedimento habitual. Adicionalmente, os resultados obtidos suportam a 
utilização de intervenções automáticas (SMS, chamadas e lembretes) combinadas com 
chamadas manuais como o método habitual de convite para rastreio do cancro do colo do útero, 
quando considerada uma disponibilidade a pagar de uma vez o produto interno bruto per capita 
em Portugal.    
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1 | INTRODUCTION 
Globally, cancer is the second cause of death, just after cardiovascular diseases, and accounts 
for an expenditure of around 1.5% of the world’s gross domestic product.1,2 In 2018, an 
estimated 18.1 million new cancer cases and 9.6 million cancer deaths occurred worldwide.3 
Considering both sexes, the most commonly diagnosed cancer was lung cancer (accounting for 
11.6% of all cancer cases), followed by breast (11.6%), colorectal (10.2%), prostate (7.1%) and 
stomach cancer (5.7%).3,4 Lung cancer was also the first cause of death (accounting for 18.4% of 
all cancer deaths), followed by colorectal (9.2%), stomach (8.2%), liver (8.2%) and female breast 
cancer (6.6%).3,4 Prostate cancer was the second most commonly diagnosed cancer among 
males, although it was the fifth most common cause of cancer death. Among women, breast 
was the most frequently diagnosed cancer and the leading cause of cancer death, while cervical 
cancer ranked fourth, both in number of cases and deaths.3 
To reduce the impact of cancer, a clear investment on cancer prevention and control 
interventions is required.5 For example, the promotion of healthier lifestyles (i.e., regular 
practice of physical activity, high intake of fruit and vegetables, low consumption of alcoholic 
beverages, avoidance of smoking) may contribute to reduce the occurrence of the most 
frequent types of cancer.6 Hepatitis B and Human Papillomavirus (HPV) vaccines are also cost-
effective and easy to implement interventions for the prevention of liver and cervical cancer, 
respectively.7,8 Additionally, organized screening is an adequate strategy for reducing cancer 
morbidity and mortality, through early detection and treatment of breast, colorectal and cervical 
cancer, or corresponding pre-malignant lesions, as applicable.9  
 
1.1 Cervical cancer epidemiology 
Cervical cancer is one of the most preventable cancers, both through HPV vaccination and 
organized screening; however, it was estimated to account for more than half a million new 
cancer cases in 2018.3,8,10 As depicted in Figure 1, the age-specific incidence is close to zero for 
the first age groups and increases with age, peaking at 36.6/100 000 women in the 55-59 age-
group and decreasing thereafter.11 
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Figure 1. Global age-specific incidence rates of cervical cancer per 100 000 women in 2018. 
Compiled from Cancer Today (2018).11 
 
Cervical cancer is the second most frequent cancer among women in low-income countries, 
although it ranks twelfth in high-income countries.4 The age-standardized incidence and 
mortality rates worldwide are depicted in Figure 2. 
After the implementation of organized screening, the age-standardized incidence rates (world 
standard population) decreased markedly since the 1970s among Northern European countries 
(i.e., Denmark, Finland, Iceland, Norway, Sweden) and after the 1990s, the rates also decreased 
in Central and South Europe, North America and some Central and South American countries 
(i.e., Brazil, Colombia, Costa Rica, Ecuador).12  
The CONCORD-2 study showed that globally, the age-standardized 5-year net survival rate 
(International Cancer Survival Standard weights) was above 50% for most countries, although in 
Europe it ranged from 60 to 69%.13 
In 2018, cervical cancer was the fourth leading cause of female cancer death in the world, 
estimated to account for over 310 000 deaths, and ranked third among women aged 15 to 44 
years.4 The age-standardized mortality (world standard population) was 9-fold higher in low-
income countries than in high-income countries, with estimates of 22.1 and 2.5/100 000 women, 
respectively.4 
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Figure 2. Cervical cancer incidence and mortality rates in 2018. 
ASR (World) – Age-standardized rate (world standard population). Reproduced from Cancer Today 
(2018).14  
 
Cervical cancer mortality decreased over the last decades in most countries, which can be 
explained by the wide implementation of cervical cancer screening and by a reduction in the 
prevalence of HPV persistent infection.10,15,16 This reduction in mortality was more notorious 
among the Nordic European countries, particularly in Iceland and Finland where the age-
standardized mortality rates (world standard population) decreased between 1986 and 1995, 
around 76% and 73%, respectively.17 The crude incidence rate of cervical cancer is projected to  
steeply decrease or remain stable until 2030, resulting in half a million to 700 000 new cases of 
cervical cancer per year.16 
Cervical cancer is the eighth most common cause of cancer among Portuguese women and 
accounts for a total of 750 new cases and 340 deaths each year.18 The age-standardized 
incidence rate (world standard population) in 2018 was estimated at 8.9/100 000 women, which 
Incidence 
Mortality 
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is lower than the mean European value of 11.2/100 000 women, although higher than the mean 
among Western European countries of 6.8/100 000 women.18 The Portuguese cancer registries 
only have cervical cancer incidence data for the time-period 2001-2010, however, the available 
evidence shows a slight decrease in the age-standardized incidence rate (world standard 
population) from 10.8/100 000 women in 2001 to 8.9/100 000 women in 2010.19,20 
The Portuguese age-standardized mortality rate of cervical cancer (world standard population) 
decreased slightly between 1981 and 2018, with corresponding estimates of 3.1 and 2.8/100 
000 women.21 The most recent estimates were lower than the mean European value of 3.8/100 
000 women, although higher than the mean value among Western Europe countries of 2.1/100 
000 women.18  
 
1.2 Pathophysiology and natural history of cervical cancer 
Cervical cancer is a neoplasia caused by the persistent infection with HPV, which occurs more 
frequently in the transformation zone of the cervix, that corresponds to the junction between a 
stratified squamous epithelium of the ectocervix and a columnar epithelium of the endocervical 
canal.10,22 The HPV virus can also cause other malignant tumours, such as cancers of the vulva, 
anus, penis, vagina or oropharynx, as well as benign lesions, including anogenital condylomas, 
genital warts or laryngeal papillomatosis.23–26  
The development of cervical cancer occurs through four main steps: 1) HPV transmission and 
infection of the cervix epithelium; 2) persistence of the viral infection; 3) progression of the 
infected cells to a precancerous lesion; 4) invasion of the surrounding tissues.27 Figure 3 depicts 
the development of cervical cancer along with the cytohistologic classification of the cervical 
lesions associated with HPV infection.  
The HPV is usually transmitted through sexual contact, that allows the virus to colonize and enter 
the cervical mucosa using micro abrasions or anatomic small tears of the epithelium.24,27–29 Most 
of the infections of the cervix are eliminated or supressed by cell-mediated immunity in one to 
two years, although some of them may persist and progress to precancerous lesions. The latter 
are expected to occur if the infection is caused by a high-risk HPV type (i.e., type of HPV that has 
a high potential to cause cervical cancer), which has the ability to colonize the stem cells of the 
mucosa and use their machinery to originate newly infected cells that can invade the 
surrounding tissues.24,27,28 The low-risk HPV types only unfrequently reach the stem cells and 
immortalize the viral production, so they have a very limited oncogenic potential.30 
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Figure 3. Description of the evolution from HPV infection of the cervix to the development of an 
invasive cervical cancer and corresponding classification of the lesions. * 
CIN - Cervical intraepithelial neoplasia. HPV - Human papillomavirus. HSIL - High-grade squamous 
intraepithelial lesion. LSIL - Low-grade squamous intraepithelial lesion. 
*The thickness of the grey arrows is proportional to the frequency of the described phenomena. †Cell-
mediated immunity is responsible for clearing most HPV infections. Source: based on Bosch, F X et al. 
(2002) and Schiffman, M et al. (2007).22,27  
 
Currently, there is enough evidence to support genotypes 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 
58, 59 as high-risk and genotypes 6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 81 as low-risk, although 
the level of evidence is still limited for genotypes 26, 30, 34, 53, 66, 67, 68, 69, 73, 82, 85, 
97.24,31,32 Genotype 16 is the most frequent, with a global weighted prevalence (calculated as a 
pooled prevalence of 194 studies, weighted by study size and further standardized by world’s 
geographical structure) among women with no abnormal findings in cytology of 3.2%, followed 
by genotype 18 with a weighted prevalence estimated at 1.4%.33 The most commonly detected 
genotypes in cervical cancer cases are the following, by decreasing frequency: 16, 18, 45, 31, 33, 
52, 58, 35, 59, 56, 39, 51, 73, 68 and 66.34 HPV 16 and 18 were detected in around 70% of all 
cervical cancer cases worldwide and are also the most commonly identified genotypes in cervical 
cancer cases in Portugal, with an estimated crude prevalence of 58.2% and 9.2%, 
respectively.24,34,35  
Despite carcinogenic potential of HPV infection, other cofactors are also required for the 
progression from HPV infection to cervical cancer, namely environmental exposures (e.g., 
contraceptive use, smoking) or host characteristics (e.g., high parity, co-infection with HIV).24,26 
Although uncertainties remain, other cofactors may also promote the progression to cervical 
cancer, namely the immunosuppression caused by organ transplant, so as the co-infection with 
Herpes simplex virus 2 or Chlamydia trachomatis.24  
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HPV epidemiology 
The global weighted prevalence of HPV infection (calculated as a pooled prevalence of 194 
studies, weighted by study size and further standardized by world’s geographical structure), 
among women with no abnormal findings in cytology, was estimated at 11.7% (95% confidence 
interval (CI): 11.6% to 11.7%) in 2010.33 Women aged 0-24 years have the highest weighted  HPV 
prevalence (pooled estimate, weighted by study size and standardized by world’s geographical 
structure), with a value of 24.0% (95% CI: 23.5% to 24.5%), which decreases as women become 
older, reaching values of 13.9% (95% CI: 13.6% to 14.1%), 9.1% (95% CI: 9.0% to 9.2%) and 4.2% 
(95% CI: 4.2% to 4.3%), for the age-groups 25-34, 35-44 and 45-54, respectively, although for 
the age-group ≥55 years the prevalence was higher and estimated at 7.5% (95% CI: 5.0 to 
11.0%).33 This pattern may be explained because young women have sexual relations more often 
and commonly with more than one partner, increasing the potential to be infected with HPV; 
while older women more often have a single partner and less sexual relations.25,30,33 On an 
analysis by region, the weighted HPV prevalence (pooled estimate, weighted by study size and 
standardized by world’s geographical structure) was lowest in Western Asia (1.7%, 95% CI: 1.1% 
to 2.5%) and highest in Eastern Africa (33.6%, 95% CI: 30.2% to 37.1%).33 In Europe, the weighted 
HPV prevalence (pooled estimate, weighted by study size and standardized by world’s 
geographical structure) was 14.2% (95% CI: 14.1% to 14.4%), with the lowest estimates observed 
in Southern Europe (8.8%, 95% CI: 8.5% to 9.0%) and the highest in Eastern Europe (21.4%, 95% 
CI: 20.1 to 22.7%).33  
 
1.3 Cervical cancer prevention and control strategies 
Reductions in cervical cancer incidence and mortality can be achieved through the 
implementation of HPV vaccination and organized screening, both being safe, effective and cost-
effective interventions recommended by the World Health Organization (WHO).15,36 
 
1.3.1 HPV vaccination 
The approval for human use of the first HPV vaccine in 2006 challenged the role of organized 
screening as the main strategy of cervical cancer prevention.37 This  promoted a paradigm shift, 
from secondary prevention, based on the early detection of malignant and pre-malignant lesions 
through organized screening, to primary prevention. Currently, a total of three different 
vaccines targeting HPV were approved for commercial use to prevent cervical cancer: a) bivalent 
vaccine (Cervarix®, GlaxoSmithKline), targeting HPV types 16 and 18; b) tetravalent vaccine 
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(Gardasil®, Merck & Co, Inc.), targeting HPV types 6, 11, 16, 18; c) nonavalent vaccine (Gardasil 
9®, Merck Sharp & Dohme Corp.), targeting HPV types 6, 11, 16, 18, 31, 33, 45, 52, 58.38–41 The 
bivalent vaccine showed an efficacy of 91.6% (95% CI: 64.5% to 98.0%) against persistent 
infection with HPV 16/18 (i.e., positivity for HPV 16/18 in at least two moments, separated by 
six months) and 100% (95% CI: 47.0% to 100%) for the prevention of cytological abnormalities 
produced by HPV 16/18.38 Additionally, it was also effective against CIN2+ lesions caused by HPV 
16/18 in 92.9% (95% CI: 79.9% to 98.3%) of the vaccinated women, after a mean follow-up of 
approximately three years.39 The efficacy in the prevention of CIN2+ lesions was higher when 
the tetravalent vaccine was used, with an estimate of 98% (95% CI: 86% to 100%), after a similar 
mean follow-up time.41 
A randomized controlled trial was conducted to compare the immunogenicity and incidence of 
high-grade cervical, vulvar and vaginal disease in women immunized with the nonavalent 
vaccine (intervention group) with those submitted to the tetravalent vaccine (control group).40 
The antibody response to HPV 6, 11, 16, and 18 was noninferior in the group of women 
immunized with the nonavalent vaccine. The crude incidence rate of high-grade cervical, vulvar 
and vaginal disease caused by any HPV genotype was 14.0/1000-person years in both groups. 
Additionally, the crude incidence rate of high-grade cervical, vulvar and vaginal disease caused 
by HPV genotypes 31, 33, 45, 52 and 58 was 0.1/1000 person-years in the intervention group 
and 1.6/1000 person-years in the control group, with a corresponding efficacy of 96% (95% CI: 
80.9% to 99.8%). All vaccines fulfilled high standards of safety and proved to be well tolerated.38–
41 
Many economic evaluations of HPV vaccines were already conducted to support their adoption, 
at a population level.  For example, in the Netherlands it was shown that the use of bivalent HPV 
vaccines are a cost-effective intervention, with an incremental cost-effectiveness ratio (ICER) of 
€5815 per quality-adjusted life year (QALY), which is inferior to the national willingness-to-pay 
threshold of €20 000/QALY.42 The cost-effectiveness of the combined use of organized cervical 
cancer screening with an HPV vaccine (bivalent or tetravalent) has been shown in Canada and 
Germany.43,44 However, the previously published studies are still insufficient to determine if the 
nonavalent vaccine is more cost-effective than the bivalent or quadrivalent vaccines, particularly 
in a scenario of simultaneous implementation of organized screening.45   
Considering the available evidence, the WHO advocates the inclusion of one HPV vaccine in all 
National Vaccination Plans, in accordance with the economic resources available in each 
country.8 In Portugal, the HPV vaccine was included in the National Vaccination Plan in 2008 and 
currently the immunization is recommended to all 10-year old girls using two doses of the 
nonavalent vaccine.46  
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The WHO also defines that even if HPV vaccines are implemented at a population level, 
organized cervical cancer screening is still needed and will probably remain necessary in the 
future, even in areas where population access to the HPV vaccine is ensured.8 This technical 
position is explained because the population uptake of the HPV vaccine is expected to be largely 
inferior to 100%, since women may be uninformed or voluntarily not want to be vaccinated.8,47,48 
Additionally, the vast majority of women in the population are no longer in the age-group 
eligible for HPV vaccination and, therefore, the only preventive strategy available is cervical 
cancer screening.8,47,48  
 
1.3.2 Cervical cancer screening 
The development of cervical cancer screening began in 1928 with Papanicolaou, who was the 
first to describe the use of exfoliative cytology (also referred to as conventional cytology) to 
identify women with invasive cervical cancer.49 In this technique, a health professional collects 
cells from the cervix using a brush and transfers them into a glass slide, which after staining, is 
submitted to microscopic observation.49 Three decades later, cytology also started to be used to 
detect premalignant lesions of the cervix.15,50 This promoted the wide adoption of cytology as 
screening method, since it was able to detect both invasive cervical cancer cases as well as 
precursor lesions.15,50  
In the beginning of the 1990’s, the use of liquid-based cervical cytology allowed an increase in 
the detection of premalignant lesions, a decrease in the proportion of glass slides with 
insufficient epithelial cells, as well as a decrease in the time required to perform and interpret a 
cervical cytology.15,51 In this screening test, cervical cells are collected and transferred to a liquid 
preservative solution and, after removing the non-epithelial cells from the sample, a glass slide 
is prepared for microscopic observation.15 
The most recently developed screening tests aim the detection of DNA of high-risk HPV 
strains.52–54 This type of test is applied to exfoliated cervical cells and has the advantage over 
cytology of requiring minimal human resources in the lab to process the sample, stain or submit 
it to microscopic observation.53 Since the result of the test is achieved with no human 
intervention, it also reduces the interobserver variability that occurs in cytology while 
interpreting the glass slides.53 HPV tests have further improved to simultaneously detect high- 
and low-risk HPV and are currently available in the market for human use (e.g., Hybrid Capture 
2®).53  
In settings where financial, technical and human resources are scarce, cervical cancer screening 
may be conducted through the visual inspection of the cervix using acetic acid (VIA), which 
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requires a low level of technology and organization to be implemented.55 This method is based 
on the application of a 3-5% solution of acetic acid in the cervix and a subsequent naked-eye 
observation of any lesion in the cervix.55 A malignant or premalignant lesion is identified by its 
acetowhite color, which is different from the usual reddish color of the cervix.55 Although VIA 
has a sensitivity similar to that observed in cytology to detect malignant and premalignant 
cervical lesions, it has a lower specificity.15 
The different screening methods available in high-resource settings have been contrasted in 
several studies. For example, in a randomized controlled trial that included women aged 30-69 
years, conventional cytology and high-risk HPV tests were compared as screening strategies to 
detect cervical cancers and high-grade premalignant lesions.56 The sensitivity of high-risk HPV 
tests was higher than conventional cytology in the detection of CIN 2+ lesions, with 
corresponding estimates of 94.6% (95% CI: 84.2% to 100%) and 55.4% (95% CI: 33.6% to 77.2%). 
However, the specificity was lower for high-risk HPV tests in comparison with conventional 
cytology, with values of 94.1% (95% CI: 93.4% to 94.8%) and 96.8% (95% CI: 96.3% to 97.3%), 
respectively. The different screening methods have also been studied in a pooled analysis of four 
randomized controlled trials that compared cytology (conventional or liquid-based) with high-
risk HPV tests, in women aged 20-64 years followed for a median of 6.5 years.57 This study 
showed that the crude incidence rate of cervical cancer was similar between both screening 
methods during the first two and a half years (incidence rate ratio = 0.79, 95% CI: 0.46 to 1.36). 
Thereafter, the crude incidence rate of cervical cancer was significantly lower among women 
submitted to high-risk HPV tests than among those who were tested with cytology (incidence 
rate ratio = 0.45, 95% CI: 0.25 to 0.81).  
Additionally, a recent systematic review of 40 studies estimated that the pooled sensitivity of 
conventional cytology, liquid-based cytology and high-risk HPV tests in the detection of CIN2+ 
lesions were 62.5% (95% CI: 46.8% to 76.5%), 72.9% (95% CI: 70.7% to 75.0%) and 89.9% (95% 
CI: 88.6% to 91.1%), respectively, with a corresponding specificity of 96.6% (95% CI: 94.9% to 
98.1%), 90.3% (95% CI: 90.1 to 90.5%) and 89.9% (95% CI: 89.7% to 90.0%).58  
In summary, high-risk HPV tests have a higher sensitivity detecting CIN 2+ lesions when 
compared with cytology, despite a slightly lower specificity. Additionally, women who are 
screened using high-risk HPV tests have a lower incidence rate of cervical cancer cases in 
comparison with those tested with cytology. Therefore, the available evidence supports the use 
of high-risk HPV tests as the standard method of cervical cancer screening.  
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Level of organization – from opportunistic invitations to organized screening 
Cervical cancer screening is broadly implemented worldwide, although with heterogeneous 
levels of organization across regions and countries, ranging from opportunistic invitations to 
well-organized screening programs with a population-based approach.59,60 Although both 
represent relevant strategies of cervical cancer prevention and control, organized screening is 
more cost-effective and contributes for larger reductions in cause-specific mortality.15  
The implementation of organized screening requires political will and financial commitment to 
be stated in a public official document, which should also include the screening test to be used, 
the interval between screening tests and the age-group to be targeted.59,61–63 From a technical 
perspective, it is also relevant to have a clear definition on how to perform the screening test, 
and how the biological products collected during screening have to be transported and 
processed in the lab.59,64,65 Additionally, a clinical guideline should establish the workup strategy 
and treatment plan to be applied to the participants who test positive in the screening test.59,64,65 
To achieve high standards of quality, an administrative structure should be created, to monitor 
screening implementation, assess its’ performance and report the obtained results.59,63 The 
administrative structure should also ensure that the entire eligible population is systematically 
identified and invited in each screening round, to maximize the potential of disease prevention 
and reduce health inequalities.59,65 
The less organized types of screening, also called “wild” or “opportunistic”, are usually provided 
after the recommendation of a health professional during appointments scheduled for other 
health purposes or after an individual’s decision to undergo screening.59,60,65 
Cervical cancer screening has long been recognized as an adequate strategy for early detection 
of cancer and premalignant lesions, with health gains for the population, particularly if it is 
implemented through well-organized screening programs.66 The effectiveness of organized 
screening would be ideally studied using a randomized controlled trial to compare the observed 
mortality rates among screened and non-screened populations.15 Although this has never been 
conducted, the available ecologic studies show a clear decreasing trend in cervical cancer 
mortality following the implementation of organized screening in many countries, supporting 
its’ positive impact on the population’s health.10 These types of studies were extensively 
published using data from Nordic countries, where the quality of registries is high and organized 
cervical cancer screening started to be implemented after the 1960s or 1970s.17,67 After the full 
implementation of organized cervical cancer screening, the largest decrease in age-standardized 
mortality (world standard population) was observed in Iceland, followed by Finland, Sweden, 
Denmark and Norway, with corresponding reductions of 76%, 73%, 60%, 55% and 43%, between 
1986 and 1995.17 The trends in the incidence of cervical cancer were heterogeneous across 
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Nordic countries. In Finland and Norway the age-standardized incidence (Norway reference 
population and world standard population, respectively) increased slightly, immediately after 
the implementation of organized screening.68,69 However, an overall decrease of 78% in the age-
standardized incidence (Norway reference population) was detected in Ǿstfold (the first region 
in Norway to implement organized screening) between 1959 and 1977, and a reduction in the 
age-standardized incidence (world standard population) of around 80% was observed in Finland 
between 1965 and 1990.68,69 Iceland reported a significant and continuous decline in the age-
standardized incidence (world standard population) of cervical cancer, from 15.7 to 10.4/100 
000 women between the periods of 1964-1979 and 1980-1995, respectively.17 Sweden followed 
the same pattern, with a decrease in the age-standardized incidence (Swedish census population 
in 1970) of cervical cancer from 20 to 7/100 000 women between 1968 and 1995, corresponding 
to a 3.7% reduction/year.70  
The observed reductions in the overall incidence of cervical cancer in Nordic countries after the 
implementation of organized screening were mainly due to a decrease in the incidence of 
squamous cell carcinomas, which corresponds to the histological type of tumour that is 
prevented when cervical cancer screening is implemented.10,17,67,68,70 This evidence, along with 
the clear long-term reductions of the overall incidence and mortality in cervical cancer highly 
support the effectiveness of organized screening.  
 
Cervical cancer screening in Portugal 
In Portugal, organized screening was implemented in 1990, after the approval of the first 
National Oncological Program.71 This strategic document defined women aged 25-64 years as 
eligible for cervical cancer screening, which was implemented by family doctors in primary care 
units.71 The Centro region was the first to implement a pilot cervical cancer screening program 
in 1990, followed by Madeira in 2004, Lisboa e Vale do Tejo in 2007, Norte and Alentejo in 2008 
and lastly, Algarve and Açores in 2010.72 In 2017, the complete coverage of the eligible 
population in most of the regions was achieved, except for Lisboa e Vale do Tejo and Madeira, 
where organized screening was still not fully implemented.73  
The test considered for cervical cancer screening has changed over time. Conventional cytology 
was used by family doctors during the pilot tests and initial implementation of  organized 
screening.71 In 2013, the regions of Norte and Algarve were already implementing a co-test 
strategy (i.e., the combined use of liquid-based cytology and high-risk HPV test), as part of 
organized screening.72 In the same year, the region of Alentejo was using liquid-based cytology 
and the remaining regions a conventional cytology.72 In 2017, the high-risk HPV tests were 
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defined by the Ministry of Health as the screening method to be used nationally for cervical 
cancer screening, which is currently being adopted by the different regions in the country.74 
The National Health System provides universal and free of charge access to organized cervical 
cancer screening.74 The coordination and quality monitoring of organized screening is performed 
by the General Directorate of Health (Direção Geral da Saúde) and the Regional Health 
Administrations (Administrações Regionais de Saúde).74 All women aged 25-60 years are 
considered eligible to be invited, except those who have a previous history of total 
hysterectomy, diagnosis of cervical cancer or gynaecological signs and symptoms.74 Eligible 
women are identified by the primary health care units where they are registered, which invite 
them to undergo screening every five years.75 The invitation is performed through a written 
letter that proposes a date and time for the appointment, and is personalized with the woman’s 
name, the name of the primary care unit and the name of the woman’s family doctor. Women 
may reschedule the appointment, using a phone number that is provided in the written letter 
or in-person at their primary health care unit.75 The customization of the written letters is 
automatically performed by a software (SiiMA Rastreios), but each invitation needs to be 
manually printed, folded and inserted into an envelope by a clinical secretary. Women who 
attend the appointment are screened by their family doctor, who performs a visual inspection 
of the uterus and collects cells from the cervix.75 The biologic products are labelled and 
transported to a centralized lab where a high-risk HPV test is performed.74,75 Organized screening 
coexists with opportunistic invitations that may be performed by family doctors during 
appointments scheduled for other health purposes or by gynecologists working in the private 
sector.  
 
Adherence to cervical cancer screening 
Despite the global acceptance and implementation of cervical cancer screening, the population 
adherence is frequently low, even among high-income countries.59,76 The age-standardized 
prevalence (world standard population) of cervical cancer screening utilization at least once 
during women’s life (opportunistic uptake or as part of organized screening) was estimated at 
67.9% (95% CI: 67.6% to 68.2%), in a survey that comprised 57 countries with different levels of 
development.76 However, the age-standardized prevalence (world standard population) of 
women submitted to cervical cancer screening during the last three years was only 39.6% (95% 
CI: 39.3% to 40.0%) globally and 18.5% (95% CI: 18.3% to 18.8%) in developing countries.76  
An analysis of the implementation of organized cervical cancer screening in Europe, conducted 
in 2017, showed that  the population coverage (i.e., proportion of women who are invited for 
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organized cervical cancer screening among those who are eligible) was 82% among  the member 
states/regions who reported this information.59 The same document describes an adherence 
proportion to organized cervical cancer screening among the invited women of only 41%, 
although this estimate ranged from 10% to 68%, according to the considered state/region.59 
In Portugal, the uptake of cervical cancer screening by the eligible population was also described. 
Before the implementation of organized screening, a study conducted in a cohort of adults living 
in Porto (the second largest city in Portugal), estimated a life prevalence of opportunistic uptake 
of cervical cancer screening of 91.2%.77 However, among the previous users of screening, only 
6.7% were tested at three to five years intervals (i.e., the recommended periodicity).  
In a different study, that considered data of the 2005/2006 National Health Survey and included 
2191 women aged 25-64 years, the life prevalence of cervical cancer screening uptake was 
estimated at 76.5%.78 This national prevalence comprises the contribution of both opportunistic 
and organized screening, although the later was only being implemented in the region of Centro 
at the time the study was conducted.78 The uptake of cervical cancer screening was described 
to vary widely, being higher in the region of Norte (84.9%), followed by Lisboa e Vale do Tejo 
(77.9%), Algarve (70.3%), Centro (69.4%), Madeira (63.1%), Alentejo (49.4%) and Açores (46.5%). 
In 2012, the uptake of cervical cancer screening was also assessed using a representative sample 
of the Portuguese population.79 This study included women aged 25-64 years and determined a 
lifetime prevalence of cervical cancer screening uptake of 71.9% (95% CI: 66.5% to 77.3%), which 
reflects both the contribution of opportunistic testing and organized screening (covering 40% of 
the eligible population in Portugal).  
In addition to the previously presented data regarding the lifetime use of cervical cancer 
screening, evidence is also available to characterize the adherence to organized screening. The 
most recent assessment report of the National Oncologic Plan showed that every year, more 
than 200 000 women are invited for testing and around 130 000 are screened.73 The proportion 
of women who adhered to organized cervical cancer screening, among those who were invited, 
increased from approximately 30% in 2009 to over 60% in 2016.73  
Many factors have been described to influence the adherence to cervical cancer screening, 
which should be considered while designing interventions to promote the participation of the 
eligible population. For example, higher levels of education78,80–82, white-collar jobs83 and a 
higher income78,80–83 are associated with a higher adherence to cervical cancer screening. 
Migrants or women who are non-fluent in the country’s mother tongue usually have an inferior 
adherence to screening.80,83,84 An association between the infrequent use of primary health care 
services78,80,85, being unemployed82,83 or unmarried80–83 and a low participation in cervical cancer 
screening has also been described. Regarding the effect of women’s age on adherence to 
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cervical cancer screening, the published literature provides conflicting results. Some authors 
showed that the adherence is lower for the age extremes of the target population77,78,81,83 
although others describe that adherence increases with age.78,80,82,85 
 
Strategies to improve adherence to cervical cancer screening 
Although cervical cancer screening is still recommended, its’ financial sustainability will be 
threatened by the simultaneous implementation of HPV vaccination.47 This is expected to occur 
since the number of women that need to be screened to prevent a cancer death will increase, 
while the fixed costs of organized cervical cancer screening will remain constant (i.e., costs with 
quality assurance and monitoring, training of the health professionals, development of technical 
guidelines). Therefore, organized cervical cancer screening needs to be reshaped to ensure its’ 
cost-effectiveness. This may be achieved through larger intervals between screening tests, 
possibly starting at older ages and using different screening strategies for vaccinated and non-
vaccinated women.47,48,86 In addition to these possible modifications, affordable interventions 
are also required to increase the population’s participation, in order to maximize the efficiency 
of organized cervical cancer screening. 
Many interventions intending to increase adherence to cervical cancer screening have already 
been evaluated, including: a) reminders – printed letters/postcards87–93, short message systems 
(SMS)94 or operator dependent phone calls90,91,95–97 used to recall previously non-adherent 
women or to announce that screening date is due; b) small media98–102 – printed materials, 
namely letters, posters or leaflets that are used to describe and promote screening, using 
different levels of customization; c) one-o-one education101–103 – interviews conducted by 
telephone or in person to describe cervical cancer screening, but also to overcome any perceived 
barrier, that may block adherence to organized screening. A previous systematic review showed 
that all the mentioned types of strategies were effective, with an absolute median adherence 
increase of 10.2% (Percentile 25 [P25]-Percentile 75 [P75]: 6.3% - 17.9%) when reminders were 
used, an increase of 4.5% (P25-P75: 0.2% - 9.0%) following small media and an increase of 8.1% 
(P25-P75: 5.7% - 17.3%) when one-o-one education strategies were implemented.104  
Despite the available evidence, only a few studies have tested stepwise interventions, applied 
sequentially until women adhere to cervical cancer screening.87,90,91 This type of approach is able 
to increase adherence at an affordable cost, since more automated and easy to implement 
interventions could be used first to invite all the eligible population and the remaining non-
adherent women would receive highly personalized and more costly strategies. The few studies 
that used stepwise interventions had no increasing level of customization105; did not comprise 
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low-cost or non-operator dependent strategies87,90,91; had no population-based approach, 
targeting only minority groups or deprived settings87.  
The implementation of strategies to increase adherence to cervical cancer screening at a 
population level requires evidence of their effectiveness, but also cost-effectiveness, which was 
reported only occasionally. The CRIVERVA study97 tested the effect of written letters, written 
letters + leaflets, written letters + leaflets + reminder manual phone calls  in comparison with no 
intervention and calculated an incremental cost per 1% absolute increase in adherence of €2.8, 
€11.0 and €13.7, respectively. Other studies reported the incremental cost per additionally 
performed pap smear. For example, a randomized controlled trial conducted in Sweden tested 
an intervention based on manual phone calls + written letters in comparison with the standard 
of care invitation (i.e., written letter) and estimated an incremental cost of €151.4 per additional 
pap smear106. In a different study, interventions based on a written letter + manual phone call, 
two manual phone calls or two written letters were compared with the standard of care (i.e., 
written letter) and were estimated to have an incremental cost per additional pap smear of $185 
(≈€158), $305 (≈€261) and $1117 (≈€955), respectively.91  
The few previous studies that reported an economic analysis of strategies to increase adherence 
to cervical cancer screening have several limitations, namely: a) avoided deaths or quality-
adjusted life years (QALYs) were not defined as outcomes in the conducted analyses, considering 
only adherence to cervical cancer screening as the only benefit91,95,97,103,106,107; b) costs were 
calculated from the provider perspective (i.e., includes the costs incurred by a health institution 
when providing a health service), but not from the societal perspective (i.e., includes provider 
costs and the costs incurred by the women to access the service)91,95,97,103,106,107; c) discount rates 
were not applied to future costs or benefits91,95,97,103,107; d) the uncertainty of the economic 
model parameters was not addressed, namely through a sensitivity analysis.91,95,97,103; e) training 
costs of the health professionals required to implement the tested interventions were not 
considered in the economic model91,95,97,107. 
The ideal invitation to cervical cancer screening should be effective and have an affordable cost 
per women invited, ensuring a cost-effective balance. An adequate assessment of interventions 
that may promote adherence to cervical cancer screening is required, namely through the 
rigorous quantification of their effectiveness and corresponding costs. High-quality cost-
effectiveness analyses should be conducted to allow policy makers to compare the different 
invitation strategies available and decide on their implementation, maximizing the health 
benefits of the scarce financial resources. 
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2 | OBJECTIVES 
Organized screening and HPV vaccination are effective strategies for reducing cervical cancer 
mortality. Although the latter is expected to represent the most important strategy to prevent 
cervical cancer in the future, organized screening will remain necessary at least for non-
vaccinated women. However, the sustainability of organized programs may be threatened 
because adherence to organized screening is often low and the increasing use of HPV 
vaccination will reduce the number of eligible women. Therefore, affordable interventions able 
to increase the participation in organized programs are needed to ensure the cost-effectiveness 
of screening strategies. This may be achieved through the combination of automated and low-
cost invitations to cervical cancer screening applied to the entire population and more expensive 
and patient-tailored interventions for the remaining non-adherent women.  
Using a population-based approach, this work intends to assess the effectiveness and cost-
effectiveness of an invitation strategy, with an increasing level of customization and cost, to 
improve women’s adherence to organized cervical cancer screening, in comparison with a 
written letter invitation (i.e., the standard of care). The intervention to be tested includes 
automated text messages/phone calls/reminders (step 1), manual phone calls performed by 
clinical secretaries (step 2) and face-to-face interviews conducted by family doctors (step 3), 
applied sequentially to women remaining non-adherent after each step.  
 
This thesis comprises the following specific objectives:  
 
1) To test the superiority of an invitation strategy based on step 1, steps 1+2 and steps 
1+2+3 in relation to the standard of care (Papers I, II, III and IV);  
2) To compare the cost-effectiveness of an invitation based on step 1, steps 1+2 and steps 
1+2+3 with the standard of care (Paper V).  
 
The first objective was accomplished through a multicentre, parallel, population-based 
randomized controlled trial (Stepwise Strategy to improve Cervical Cancer Screening Adherence 
- SCAN trial), involving women eligible for cervical cancer screening, aged 25 to 49 years, 
registered in Porto Ocidental or Marão e Douro Norte Health Care Areas, with an available 
mobile phone in the National Health Service database. Women randomized to the control group 
were invited through a written letter and those randomized to the intervention group were 
invited through a stepwise strategy based on progressively more complex and costly 
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interventions targeting women with increasingly high levels of unresponsiveness to screening 
invitations. 
The second objective was addressed through an economic study, that compared the cost-
effectiveness of the four competing invitation strategies to cervical cancer screening tested in 
the SCAN randomized controlled trial. The main outcome of the model was the cost per QALY 
measured over a five-year time horizon. Adherence to cervical cancer screening after each of 
the competing interventions was obtained from the SCAN trial and the corresponding QALYs 
were estimated based on previous studies. Costs were calculated from the societal and provider 
perspective, and were estimated based on Portuguese sources, or if not available, the 
international literature. 
A detailed description of the methods is provided in the protocol of the randomized controlled 
trial (Paper I), and in each of the articles/manscripts adressing the specific objectives. 
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3.2 Paper II 
 
Firmino-Machado J, Vilela S, Mendes R, Moreira A, Lunet N. Stepwise strategy to improve 
cervical cancer screening adherence (SCAN-Cervical Cancer) – Automated text messages, phone 
calls and reminders: population based randomized controlled trial. Prev Med. 2018;114:123–33. 
 
Papers | 48 
 
  
Papers | 49 
 
  
Papers | 50 
 
  
Papers | 51 
 
 
  
Papers | 52 
 
  
Papers | 53 
 
  
Papers | 54 
 
 
  
Papers | 55 
 
  
Papers | 56 
 
  
Papers | 57 
 
 
  
Papers | 58 
 
 
 
 
  
 
 
 
Papers | 60 
 
3.3 Paper III 
 
Firmino-Machado J, Mendes R, Moreira A, Lunet N. Translating evidence into practice: insights 
on the reporting of trial results to health professionals and institutions (submitted).  
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INTRODUCTION 
The communication of results from public health interventions to the professionals involved in 
their implementation and evaluation is an important component of research in this field, and is 
essential to have the support of health professionals who will be involved in their 
implementation and evaluation.1 In addition to academic publications and presentations in 
scientific fora, this requires the communication of results using multiple means, to reach 
different targets, including easy-to-read reports directed to broad audiences.2 
Some strategies that promote an effective communication of results have been described, such 
as tailoring the message to include information that is specific for each individual/institution or 
selecting the most relevant results for each audience segment.3  
 
PROPOSED FRAMEWORK 
Here we propose a framework to report the main findings of experimental studies to health 
institutions and professionals involved in the assessment of the effectiveness of an intervention, 
based on the trial Stepwise strategy to improve Cervical Cancer Screening Adherence (SCAN-
Cervical Cancer), which was previously described in detail elsewhere.4,5 This study tested the 
invitation to cervical cancer screening through automated and personalized text messages, 
phone calls and reminders to increase the adherence to cervical cancer screening, in relation to 
the standard of care (written letter). The participants were women eligible for cervical cancer 
screening, aged 25 to 49 years, registered at one of the 13 participant primary care units, 
including urban and rural areas (Figure 1 of the Appendix), with an available mobile phone 
registered at the National Health Service database. The primary outcome was the adherence to 
screening 45 days after implementing the interventions.  
We produced a two-page template (please see Appendix) to disseminate the evidence produced 
by a pragmatic randomized controlled trial to the involved health professionals and institutions. 
It comprises the description of the study rationale, design of the trial, settings and participants, 
interventions, results of the study, discussion of the internal and external validity, summary of 
main findings, as well as funding and conflict of interest. A detailed analysis of each section is 
presented in Box 1.  
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Box 1 – Template proposed to communicate the main findings of experimental studies. 
1| Rationale for the investigation 
Identification, magnitude and relevance of the problem to be tackled with the intervention. This 
section should also identify the knowledge gaps addressed by the investigation. 
  
2| Study description 
2.1 – Objective and study design 
Objective of the investigation and study design details, such as number of centers, 
randomization units, blinding and other methodological features with potential impact on 
internal and external validity.  
  
2.2 – Settings and participants  
Inclusion and exclusion criteria, as well as the characteristics of the areas/institutions involved 
in the study. This information can be communicated using plain text, but also graphical 
representations, such as flowcharts or diagrams (e.g., CONSORT diagram). Maps can also be 
used to depict the geographical distribution of the recruiting sites (e.g., Figure 1 of the 
appendix).6  
  
2.3 – Tested intervention and control 
Tested intervention and comparator, and study implementation. Flowcharts, process content 
diagrams or swim lane activity diagrams may be useful to improve the understanding of complex 
study interventions.7 These graphical elements may be particularly useful when the study 
designs are complex (e.g., Figure 2 of the Appendix). 
  
3| Results of the trial 
3.1 – Overall effect of the intervention. 
Overall results of the intervention can be presented using different effect measures, along with 
precision estimates (e.g., 95% confidence intervals), and p-values for comparisons between 
intervention and control groups. 
Measures such as the number needed to treat (NNT), as these are easily interpreted by clinicians 
and illustrate the number of patients that need to be treated to prevent one adverse outcome. 
NNT can also be adapted to address different research topics, namely vaccination (number 
needed to vaccinate) or screening (number needed to screen). 
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3.2 – Effect of the intervention by recruiting site and population subgroups. 
Effect estimates stratified by recruiting sites, for benchmarking of results. 
Funnel or forest plots may be used to depict strata-specific results. Funnel plots are commonly 
used to access publication bias in meta-analyses, but they can also be used to depict the 
heterogeneity of effect measures across study centers.8 
This format of graphic display of the results avoids the use of confidence intervals, though 
instructions for a proper interpretation of the funnel plots may be needed (e.g., Figure 3 of the 
Appendix). Forest plots could be used instead, for graphical presentation of center-specific data, 
as well as to depict the effect of the intervention stratified by any relevant baseline 
characteristic, namely sociodemographic variables or presence of comorbidities (e.g., Figure 4 
of the Appendix), enabling the identification of participants sub-group(s) in which the 
intervention is more/less beneficial. 
  
4| Internal and external validity 
4.1 – Internal validity 
Threats to the internal validity of the study should be addressed in this section and may comprise 
topics such as imbalance of participants baseline characteristics between intervention and 
control groups, contamination, differential losses to follow-up or misclassification of the 
outcome, among others.  
  
4.2 – External validity 
The limits to the generalizability of study findings, i.e. “the degree to which results of a study 
may apply, be generalized, or be transported to populations or groups that did not participate 
in the study” 9, along with the extent to which the trial may be considered pragmatic should be 
addressed.  
A more comprehensive and systematic assessment of the pragmatic nature of the trial may be 
achieved using tools such as the PRagmatic Explanatory Continuum Indicator Summary 2 
(PRECIS-2).10 
  
5| Summary of main findings 
The summary of the main findings may be complemented by a statement on the potential 
applicability or usefulness of the intervention in the specific setting being targeted by the report. 
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6| Funding and conflict of interest 
All project grants or supporting funds of the research project should be presented, so as any 
conflict of interest of the research team, as defined by the International Committee of Medical 
Journal Editors (ICMJE).  
 
USE OF THE PROPOSED TEMPLATE IN SCAN TRIAL 
A personalized report was assembled for each primary care unit involved in the trial, using the 
proposed template. Each document was signed by the principal investigator and sent by e-mail 
to all the involved health professionals and institutions. The use of a two-page report allowed 
health professionals to quickly read it but also to print and post it as poster in each primary care 
unit, promoting the dissemination of findings.  
A meeting with the primary care unit was scheduled to discuss the overall results of the trial, 
but also the effect of the intervention in each recruiting site. The same presentation was 
conducted with the coordinators of the primary care units involved.  
Through these strategies we have promoted the discussion and dissemination of the study 
results to the involved health professionals and possibly contributed to a sustainable 
implementation of the tested intervention.  
In conclusion, this two-page template can be easily customized according to the intended 
audience. This work may be useful to disseminate study findings of experimental studies, 
although further research is needed to quantify the acceptance of the proposed template by 
different groups of health professionals (medical doctors, nurses, health managers) and types 
of institutions (primary health care units, hospitals), but also to determine which is the most 
effective strategy to disseminate findings of distinct nature.  
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APPENDIXES 
Appendix 1 - Template to disseminate the evidence produced by a randomized controlled trial to the 
involved health professionals and institutions. 
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ABSTRACT 
Background  
Cervical cancer screening is effective in reducing mortality, but adherence is generally low. We 
aimed to investigate the cost-effectiveness of a stepwise intervention to promote adherence to 
cervical cancer screening in Portugal. 
 
Methods  
We developed a decision tree model to compare the cost-effectiveness of four competing 
interventions to increase adherence to cervical cancer screening: (a) a written letter (standard 
of care); (b) automated short message service text messages (SMS)/phone calls/reminders; (c) 
automated SMS/phone calls/reminders + manual phone calls; (d) automated SMS/phone 
calls/reminders + manual phone calls + face-to-face interviews. The main outcome measure was 
cost per quality-adjusted life year (QALY) measured over a 5-year time horizon. Costs were 
calculated from the societal and provider perspectives.  
 
Results  
From the societal perspective, the optimal strategy was automated SMS/phone calls/reminders, 
below a threshold of €9394 per QALY; above this and below €172339 per QALY, the most cost-
effective strategy was automated SMS/phone calls/reminders + manual phone calls and above 
this value automated SMS/phone calls/reminders + manual phone calls + face-to-face 
interviews. From the provider perspective, the ranking of the three strategies in terms of cost-
effectiveness was the same, for thresholds of €4286 and €167230 per QALY, respectively.  
 
Conclusions  
Assuming a willingness-to-pay threshold of one time the national gross domestic product 
(€22398 /QALY), automated SMS/phone calls/reminders + manual phone calls is a cost-effective 
strategy to promote adherence to cervical cancer screening, both from the societal and provider 
perspectives. 
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INTRODUCTION 
Cervical cancer is the fourth most commonly diagnosed cancer and cause of cancer death in 
women globally, estimated to account for more than 310 000 deaths per year.1 A substantial 
part of the cases of cervical cancer can be prevented by human papillomavirus (HPV) vaccination 
and screening.2,3 The latter has been proven effective in decreasing cause-specific mortality, 
potentially up to 80%, and will remain necessary even with widespread HPV vaccination, to cover 
non-vaccinated women.4 However, the sustainability of cervical cancer screening programs 
requires more cost-effective approaches, since the participation in organized screening is often 
low and HPV vaccination will decrease the number of eligible women.5  
The effectiveness of many different strategies to increase adherence to cervical cancer screening 
was previously investigated against the standard of care (usually written invitation letter), 
including the use of patient reminders, brochures and videos and face-to-face interviews 
performed by health professionals or researchers.6 However, previous reports often lack 
detailed cost information about the interventions tested, precluding a comprehensive cost-
effectiveness analysis.7–12  
Stepwise interventions using automated and inexpensive invitation strategies for the entire 
eligible population and increasingly customized and expensive methods only for non-adherent 
women, may provide an affordable solution to promote adherence to cervical cancer screening. 
The aim of this study was to compare the cost-effectiveness of a stepwise invitation strategy 
designed to increase adherence to cervical cancer screening compared with the standard of care 
(a written invitation letter), using a disease simulation model, developed with patient-level data 
and data from the published literature.  
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METHODS  
We estimated the cost-effectiveness of the interventions previously evaluated in the Stepwise 
Strategy to improve Cervical Cancer Screening Adherence (SCAN) study.13,14 This is a multicentre, 
parallel, population-based randomized controlled trial that aimed to investigate the 
effectiveness of different strategies to increase adherence to cervical cancer screening in 
Portugal. It included a total of 1220 women eligible for cervical cancer screening aged 25 to 49 
years. Women who were randomized to the control group (n=615) were invited by a written 
letter (i.e., standard of care) and those randomized to the intervention group (n=605) were 
invited through automated short message service text messages (SMS)/phone calls/reminders; 
the invitation strategy included also manual phone calls and face-to-face interviews, applied 
sequentially to women remaining non-adherent. 
The SCAN trial was approved by the regional ethics committee – Comissão de Ética da 
Administração Regional de Saúde do Norte (reference: 20/2017) – and by the National Data 
Protection Committee (reference: 11467/2016). 
 
Model Overview 
To estimate the impact of the tested interventions on outcomes measured over a 5-year time 
horizon, including cost per quality-adjusted life year (QALY), cost per death avoided and cost per 
woman screened, we developed a decision tree model that integrated primary data from the 
SCAN trial and published data.  
Based on the SCAN trial, we defined four competing interventions for our cost-effectiveness 
model (Figure 1), as follows: (a) invitation through written letter; (b) invitation through 
automated SMS/phone calls/reminders; (c) invitation through automated SMS/phone 
calls/reminders + manual phone calls performed by a primary care unit secretary; and (d) 
invitation through automated SMS/phone calls/reminders + manual phone calls performed by a 
primary care unit secretary + face-to-face interview performed by a medical doctor. 
Regardless of the strategy used, women adherent to cervical cancer screening could have a 
positive or negative screening test result. Participants who tested positive could have no cervical 
lesion or be diagnosed with a precancerous lesion or cervical cancer. Women testing negative 
could have no cervical lesion, or have a precancerous lesion or cervical cancer that remains 
undetected. Women with a precancerous lesion (detected or not during screening) were 
considered to survive for at least five years. Cancer-specific survival estimates were used to 
define the probability of women with a cervical cancer (identified or not during screening) 
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surviving during the 5-year time horizon of the model.15–18 The model was implemented in 
TreeAge Pro 2017.19 
 
Health benefits 
The health benefits considered in the decision model are summarized in Table 1 and their 
calculation is detailed in Appendixes 1 and 2. Adherence to cervical cancer screening was 
estimated using data from the SCAN trial, at 34.0% for strategy (a), 43.0% for strategy (b), 50.6% 
for strategy (c) and 51.2% for strategy (d).13,14  
The implementation of strategies (b), (c) and (d) is dependent on the quality of mobile phone 
number registers, which is heterogeneous across primary care units. Therefore, we have 
assumed a probability of successful delivery of automated SMS/phone calls/reminders of 80.7% 
(overall estimate of the SCAN trial) in our base case and varied this parameter between 68% and 
85% in a sensitivity analysis; this range corresponds to the minimum and maximum values 
observed across the different recruiting sites in the SCAN trial.14  
The 5-year relative survival estimates and utility values assigned to each health state of the 
decision model were obtained from previously published studies. Women with a cervical cancer 
were considered to have a 5-year relative survival of 0.893 if previously tested positive on the 
screening test; 0.795 if previously tested negative on the screening test (i.e., false negatives); 
0.754 if were non-adherent to organized screening program. 15–18 All participants with a pre-
cancerous lesion or with no abnormal findings in the cytology were considered to be alive after 
5-years. The survival estimates may be influenced by the cervical cancer epidemiology and 
organization of the health services, which are different in each country. Therefore, the 
parameters were varied in plus or minus 10% in the sensitivity analysis, because these were not 
locale-specific data. 
Utility values for the different health states (i.e., false positive screening test, precancerous 
lesion, cervical cancer survivorship or death) ranged from a minimum of 0 to a maximum of 1, 
representing a health state that equals death and perfect health, respectively. Women had no 
disease but who tested positive on a screening test, i.e. the false positives, were considered to 
have a utility value of 0.9967 for a one-year period, and 1 thereafter.20 Women with a 
precancerous lesion were considered to have a utility of 0.9704 during one year and a utility of 
1 after that period.21 Those with cervical cancer, detected during screening or otherwise, who 
survived after treatment were considered to have a utility value of 0.715 for a 5-year period. 
Those who died from a cervical cancer, detected during screening or otherwise, were assigned 
a utility of 0, over the 5-year period.22 Women without cancer and no abnormal findings during 
screening were assigned a utility value of 1.23 
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Future benefits were discounted at a rate of 3% annually, based on the World Health 
Organization recommendations.24  
 
Costs 
Costs were calculated from the provider perspective, which includes the costs incurred by a 
health institution when providing a health service, and from the societal perspective, which 
additionally includes the costs incurred by the women to access the service. All future costs were 
discounted at a rate of 3% annually.24 A summary of the costs considered in the decision tree 
models is provided in Table 1 and the calculation details are described in Appendixes 3 (costs of 
the tested interventions) and 4 (costs of cervical cancer screening, curative treatment and end 
of life care). The costs incurred by the health institutions included those related with: women 
invitation to screening, screening test, workout of a positive screening test, curative treatment 
of cervical cancer and end-of-life care costs. The costs incurred by the women included those 
due to travel expenses, productivity losses because of cervical cancer and travel time to 
screening and all the required medical treatments. In the sensitivity analysis we considered 20% 
smaller costs of workout of a positive screening test, cervical cancer curative treatment and end-
of-life care, because these estimates were obtained from countries with higher gross domestic 
product (Appendix 3). Fixed costs related with the infrastructure were assumed to be the same 
between all invitation strategies and were therefore not considered in data analysis.  
An additional analysis was conducted considering only short-term costs, which comprise the 
invitation costs but do not include those related to screening and treatment and considering as 
outcome the cost per women screened. 
 
Cost-effectiveness analysis 
The incremental cost-effectiveness ratio (ICER) was calculated as the additional costs divided by 
the additional health benefits of one strategy compared to the next less-costly strategy. The 
ICERs was compared to an external willingness-to-pay (WTP) threshold to identify the most cost-
effective invitation strategy. The strategy that has the highest ICER just below the threshold is 
considered the invitation strategy that provides the most health benefit considering a budget 
constraint, i.e. the most cost-effective option.  
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RESULTS 
The 5-year costs and benefits, and cost effectiveness results are presented in Table 2, and 
detailed results from the sensitivity analysis are depicted in Table 3. 
 
5-year costs and benefits 
From the provider perspective, the total 5-year mean cost per woman invited ranged from a 
minimum of 22.7€ for strategy (b), to a maximum of 24.4€ for strategy (d).  The short-term cost 
analysis, i.e., including only invitation costs, yielded a mean cost per women invited ranging from 
a minimum of 0.1€, for strategy (b), to a maximum of 2.7€, for strategy (d). From the societal 
perspective, the total 5-year mean cost per woman invited was lowest for strategy (b) and 
highest for strategy (d), at 25.7€ and 27.9€ per women invited, respectively. The short-term 
mean cost was also lowest for strategy (b) and highest for strategy (d), at 3.1€ and 6.2€ per 
women invited, respectively. 
Regarding QALYs, strategy (a) was the least effective, with 4.6076 QALYs per women invited over 
a 5-year period, and strategy (d) was the most effective, with 4.6078 QALYs per women invited. 
The pattern was similar for the mean number of avoided deaths, with strategy (a) being the least 
effective (0.999910 avoided deaths per women invited) and (d) as the most effective (0.999930 
avoided deaths per women invited). In terms of adherence to organized screening, the least 
effective strategy was the standard of care (strategy a) and the most effective was strategy (d), 
at 34.0% and 51.2%, respectively.  
 
Cost-effectiveness results  
From the provider perspective, strategy (a) was eliminated, because it was strongly dominated 
by strategy (c), i.e., it was costlier and less effective. The ICER was 4286€ per QALY and 167230€ 
per QALY for strategies (c) and (d), respectively. From the societal perspective, strategy (a) was 
strongly dominated by strategy (b) and thus eliminated from the analysis. Strategy (c) and (d) 
had ICERs of 9394€ per QALY and 172339€ per QALY, respectively.  
 
One-way sensitivity analysis 
The ranking of the interventions and the optimal intervention in terms of cost-effectiveness did 
not change over the range of parameter values used in sensitivity analysis. Strategy (a) was 
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consistently (strongly) dominated in all analyses. Strategy (d) was also dominated when 
considering an increase in adherence over time, due to opportunistic invitations, greater than 
3%. 
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DISCUSSION 
The invitation to cervical cancer screening based on automated SMS/phone calls/reminders + 
manual phone calls was very cost-effective, both from both the societal and provider 
perspectives. Although at a national level there is no universally-accepted threshold for the WTP 
for a QALY, we interpreted the results according to the cut-offs commonly applied in cost-
effectiveness analyses of one (very cost-effective) and three times (cost-effective) the national 
gross domestic product per capita (i.e., €22398 and €67194 per QALY in Portugal in 2016).25. 
However, policy makers may have short-term budget constraints that prevent them from 
adopting the most cost-effective strategy. In this scenario, they should implement an invitation 
based exclusively on automated SMS/phone calls/reminders, which was the less costly 
intervention in the short-term, but also more effective than the standard of care. 
To the best of our knowledge, this is one of the few studies reporting on a detailed and 
comprehensive cost-effectiveness analysis of interventions that intend to promote adherence 
to cervical cancer screening. The major strength of this study is that it considers essentially 
patient level data, drawn from a methodologically robust randomized controlled trial. The 
present study also adds to most previous cost-effectiveness analyses on this topic by considering 
avoided deaths and QALYs as an outcome7–12 and by estimating costs and benefits from the 
societal perspective.7–12 Additionally, model parameter uncertainty was considered by 
conducting sensitivity analyses7,8,10,12 and future costs and benefits were discounted over time.7–
10,12 
However, some limitations of our study need to be addressed. First, the adherence to cervical 
cancer screening considered in the decision tree model was determined among women aged 25 
to 49 years, using the SCAN trial, although the remaining transition parameters, which were 
obtained from previously published studies, refer to women aged 25 to 65 years. However, the 
conducted sensitivity analysis showed that the conclusions do not change after plausible 
variations of the transition parameters. 
Secondly, strategies (b), (c) and (d) depend on the availability of updated mobile phone numbers 
on the medical records of the eligible women, both for SMS and manual phone call invitations. 
Therefore, adherence to cervical cancer screening may be smaller in areas with a lower quality 
of phone number records. However, the sensitivity analysis showed that strategy (c) will remain 
the most cost-effective intervention even if the proportion of successfully delivered automated 
interventions is just below 40%. 
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Finally, the present study considers a time-frame of five years instead of the complete lifetime 
of the women invited to cervical cancer screening. Therefore, it does not comprise the potential 
longer-term benefits due to carry-over effect of these intervention, which are expectedly larger 
among the invitation strategies that depart from the standard of care. We opted for this type of 
analysis to allow the use of more reliable parameters, particularly survival estimates, which are 
usually published for the five years after a pre-malignant or malignant disease. 
In conclusion, our study provides robust evidence for policy makers and health managers to 
define automated SMS/phone calls/reminders + manual phone calls as the new standard of care 
strategy for women invitation to cervical cancer screening, under a willingness-to-pay threshold 
of one time the national gross domestic product (€22398 per QALY), or at least to replace a 
written letter invitation by automated SMS/phone calls/reminders, which was more effective 
than the standard of care and the less costly intervention in the short-term. 
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KEY POINTS 
• This study uses patient-level data from a randomized controlled trial and data from previously 
published studies to build a decision-analytic model to assess the cost-effectiveness of 
interventions aiming to increase the adherence to cervical cancer screening.  
• Assuming a willingness to pay of €22398 per QALY, automated SMS/phone calls/reminders + 
manual phone calls was a cost-effective invitation strategy from both the societal and provider 
perspectives. 
• Invitation using a written letter (standard of care) was costlier and less effective than an 
invitation based exclusively on automated SMS/phone calls/reminders (societal perspective) or 
automated SMS/phone calls/reminders + manual phone calls (provider perspective) and 
therefore cannot be considered a cost-effective intervention.  
• These conclusions hold when uncertainty in model parameters was taken into account, 
including the probability to deliver the interventions, as well as screening and treatment costs. 
.26 
.27 
.28 
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TABLES  
Table 1 - Summary of decision tree model parameters. 
CIN - Cervical intraepithelial neoplasia. HPV - Human papillomavirus. QALY - Quality Adjusted Life Years. SMS - short message service text message. 
*All costs depicted were determined on a provider perspective. If a societal perspective is assumed, a total cost of 6.96€ will be added to all women 
who undergo screening. Details on cost calculation are presented in Appendixes 3 and 4. †Future benefits are discounted at a rate of 3% annually24 
††The parameter to be varied in the sensitivity analysis is the proportion of successfully delivered automated SMS/phone calls/reminders (range: 
0.68 to 0.85). 
Table 1 - Summary of decision tree model parameters.
Description of the transition probabilities Base case (p) Range Further details
Probability of adherence to cervical cancer screening after step (a) 0.34 (please see appendix 2 for probability calculation details)
Probability of adherence to cervical cancer screening after step (b) 0.43 0.386 - 0.432†† (please see appendix 2 for probability calculation details)
Probability of adherence to cervical cancer screening after step (c) 0.506 0.449 - 0.508†† (please see appendix 2 for probability calculation details)
Probability of adherence to cervical cancer screening after step (d) 0.512 0.451 - 0.514†† (please see appendix 2 for probability calculation details)
Probability to test positive on the screening test (any type of abnormal 
finding)
0.0195
1 Based on data from the assessment report of cervical cancer screening in the 
North Region of Portugal.
Probability to have a cervical intraepithelial neoplasia grade 2 or over 
(CIN 2+), among women who tested positive
0.17532 This corresponds to the positive predictive value of the screening test (HPV 
test+cytology) for a CIN2+ lesion.
Probability to have no abnormal cytology, among women who tested 
negative on the screening test
0.99792 This corresponds to the negative predictive value of the screening test.
Probability to have cancer among women who tested positive and have a 
CIN2+ lesion
0.017
3 The same estimate was assumed for women who tested negative on the 
screening test and had a CIN2+ lesion.
Probability to have cancer among non-screened women 0.00021 Based on data from the assessment report of cervical cancer screening in the 
North Region of Portugal. Since the prevalence of cervical cancer is only 
available for women who adhered to cervical cancer screening, the prevalence 
among the non-screened was estimated assuming a correction factor, 
previously described.4Probability to have a precancerous lesion among non-screened women 0.0193
1 It was a sumed that the probability to have a precancerous lesion is the same 
as in the screened population. Data is based on the regular assessment of 
cervical cancer screening in the North Region of Portugal. 
5-year survival probability among women with a confirmed cervical 
cancer, who previously tested positive on the screening test
0.893
5
5-year survival probability among women with a confirmed cervical 
cancer, who previously tested negative on the screening test
0.7955
5-year survival probability among women with a confirmed cervical 
cancer, who were not adherent to organized cervical cancer screening
0.7545 These women may undergo opportunistic screening. 
5-year survival probability among women with a pre-cancerous lesion 1
5-year survival of a healthy women 1
Description of cost parameters Base case(€)* Range Further details
Invitation letter 0.80 (please see appendix 3 for cost calculation details)
Automated text messages/phone calls and reminders (please see appendix 3 for cost calculation details)
             Invitation delivered 0.10
             Invitation not delivered 0.05
Secretary phone call 1.27 (please see appendix 3 for cost calculation details)
Medical doctor phone call/face-to-face interview (please see appendix 3 for cost calculation details)
             Screening scheduled 6.88
             Screening not scheduled 3.16
Screening test 5.42 (please see appendix 4 for cost calculation details)
Workout of a positive screening test 171 
6 137-171
Treatment of a precancerous cervical lesion 696 
7 557 - 696 Includes CIN 2 and CIN 3 lesions.
Treatment of an early stage cervical cancer 5229 7 4183 - 5229 This was computed assuming the mean cost between the treatment of a grade I 
and a grade II cervical cancer.
Treatment of a high stage cervical cancer 18326 7 14661 - 18326 This was computed assuming the mean cost between the treatment of a grade 
III and a grade IV cervical cancer.
End of life costs of patients with cervical cancer 64965 
8 51972 - 64965 Comprises the costs of treatment, hospital stay, appointments and emergency 
room during the 6 months before death.
Description of health state Base case       
(QALY/year)
†
Range Further details
Cervical cancer case that died 0
Cervical cancer case that survives 0.715 9 The utility of 0.715 QALY/year was considered over a 5-year period. The utility 
was computed assuming that cervical cancer survivors have the lower stage of 
the tumor. Therefore, the mean utility of stage I and stage II was considered. 
Women with precancerous lesion 0.9704 
10 A utility of 0.9704 QALY was considered during a 1-year period. After the first 
year a utility of 1 was assumed. 
Women with a positive screening test, but with no disease (false 
positive)
0.9967 11 The utility of a false positive test was considered. This was only assumed during 
a 1-year period. After this moment a utility of 1 was considered. 
Legend: QALY - Quality Adjusted Life Years. All depicted costs were determined on a provider perspective. If a societal perspective is assumed, a total cost of 6.96€ will be added to all 
women who undergo screening. Further details on cost calculation are presented in Appendix 3 and 4. †Future benefits are discounted at a rate of 3% annually. ††The parameter to be 
varied in the sensitivity analysis will be the probability t  successfully deliver the automated text messages/phone calls, that will range from 0.68 to 0.85. The variation of this 
parameter will result in the represented probabilities of adherence to cervical cancer after strategy (b), (c) and (d).  
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Table 3 - Sensitivity analysis. 
 
ICER - incremental cost-effectiveness ratio. SD - strongly dominated. SMS - short message service text message. *The table depicts the minimum 
and maximum value of the parameters assumed in the sensitivity analysis and the corresponding ICERs. †Strategy (a) - written letter; Strategy 
(b) - SMS/phone calls/reminders; Strategy (c) - automated SMS/phone calls/reminders + manual phone calls; Strategy (d) - SMS/phone 
calls/reminders + manual phone calls + face-to-face interviews. ††The difference in cost divided by the difference in adherence of one strategy, 
compared with the next more effective strategy. All the ICER values were computed using a cost-effectiveness model that assumes as outcome 
the number of Quality Adjusted Life Years. ¶Since the adherence after strategy (b) and (c) was not determined 150 days after implementing 
these interventions (as conducted for strategies (a) and (d)), a correction factor was applied to consider the possible effect of opportunistic 
invitations (Appendix 1). The minimum value of zero corresponds to the unlikely scenario where no opportunistic invitations occur. The values 
of 8.3% and 3.3% correspond to the opportunistic adherence values observed in the control group of SCAN trial that were assumed as the highest 
estimates possible to occur (Appendix 1).            
 
 
Parameter to be varied in 
the sensitivity analysis
Parameter 
range
* Strategy
† ICER
††            
(provider perspective)
Strategy
† ICER
††            
(societal perspective)
Parameter to be varied in the 
sensitivity analysis
Parameter 
range
* Strategy
† ICER
††            
(provider perspective)
Strategy
† ICER
††            
(societal perspective)
Min. 68% (b) - (b) - Min. 0.804 (b) - (b) -
(c) 6565 (a) SD (c) 4622 (a) SD
(a) SD (c) 11675 (a) SD (c) 9796
(d) 261369 (d) 266478 (d) 169630 (d) 174804
Max. 85% (b) - (b) - Max. 0.982 (b) - (b) -
(c) 4205 (a) SD  (c) 3957 (a) SD
(a) SD (c) 9314 (a) SD (c) 9003
(d) 165636 (d) 170744 (d) 164890 (d) 169935
Min. 137 € (b) - (b) - Min. 0.716 (b) - (b) -
(c) 3876 (a) SD (c) 4464 (a) SD
(a) SD (c) 8985 (a) SD (c) 9608
(d) 166820 (d) 171929 (d) 168506 (d) 173649
Max. 171 € (b) - (b) - Max. 0.875 (b) - (b) -
(c) 4279 (a) SD (c) 4106 (a) SD
(a) SD (c) 9387 (a) SD (c) 9181
(d) 167223 (d) 172332 (d) 165956 (d) 171030
Min. 557 € (b) - (b) - Min. 0.679 (b) - (b) -
(c) 5203 (a) SD (c) 1972 (a) SD
(a) SD (c) 10312 (a) SD (c) 6636
(d) 168148 (d) 173256 (d) 150726 (d) 155390
Max. 696 € (b) - (b) - Max. 0.829 (b) - (b) -
(c) 3784 (a) SD (c) 7087 (a) SD
(a) SD (c) 8893 (a) SD (c) 12735
(d) 166729 (d) 171837 (d) 187215 (d) 192863
Min. 4 183 € (b) - (b) - Min. 0% (b) - (b) -
(c) 4442 (a) SD (c) 1694 (a) SD
(a) SD (c) 9551 (a) SD (c) 6802
(d) 167387 (d) 172496 (d) 167230 (d) 172339
Max. 5 229 € (b) - (b) - Max. 8.3% (b) - (b) -
(c) 4199 (a) SD (c) 14104 (a) SD
(a) SD (c) 9308 (a) SD (c) 19213
(d) 167144 (d) 172252 (d) 167230 (d) 172339
Min. 14 661 € (b) - (b) - Min. 0% (b) - (b) -
(c) 4486 (a) SD (c) 6974 (a) SD
(a) SD (c) 9595 (a) SD (c) 12082
(d) 167431 (d) 172539 (d) 31044 (d) 37152
Max. 18 326 € (b) - (b) - Max. 3.3% (b) - (b) -
(c) 4174 (a) SD (c) 3187 (a) SD
(a) SD (c) 9283 (a) SD (c) 8296
(d) 167119 (d) 172228 (d) SD (d) SD 
End-of-life costs Min. 51 972 € (b) - (b) -
(c) 5077 (a) SD
(a) SD (c) 10185
(d) 168021 (d) 173130
Max. 64 965 € (b) - (b) -
(c) 3971 (a) SD
(a) SD (c) 9079
(d) 166915 (d) 172024
Probability to successfully 
deliver automated 
SMS/phone calls
Treatment costs of a 
precancerous lesion
Workout costs of a 
positive screening test
Treatment costs of an 
early stage lesion
Treatment costs of a high 
stage lesion
Correction applied to the 
adherence determined after 
strategy (b), to consider the 
expected increase over time 
due to opportunistic 
invitations¶
5-year relative survival among 
women with a confirmed 
cervical cancer, who previously 
tested positive on the 
screening test
5-year relative survival among 
women with a confirmed 
cervical cancer, who previously 
tested negative on the 
screening test
5-year relative survival among 
women with a confirmed 
cervical cancer, who were not 
adherent to organized cervical 
cancer screening
Correction applied to the 
adherence determined after 
strategy (c), to consider the 
expected increase over time 
due to opportunistic 
invitations¶
Papers | 106 
 
 
.   
Fi
gu
re
 1
 –
 D
e
ci
si
o
n
 t
re
e 
m
o
d
el
 o
ve
rv
ie
w
. 
SM
S 
- 
sh
o
rt
 m
es
sa
ge
 s
e
rv
ic
e 
te
xt
 m
es
sa
ge
s.
 *
W
o
m
en
 n
o
t 
re
ce
iv
in
g 
th
e 
te
st
ed
 i
n
te
rv
e
n
ti
o
n
 m
ay
 u
n
d
er
go
 s
cr
ee
n
in
g 
af
te
r 
an
 i
n
vi
ta
ti
o
n
 m
ad
e 
b
y 
th
ei
r 
fa
m
ily
 d
o
ct
o
rs
, d
u
ri
n
g 
ap
p
o
in
tm
en
ts
 s
ch
e
d
u
le
d
 f
o
r 
o
th
er
 h
ea
lt
h
 r
ea
so
n
s 
Papers | 107 
 
 
 
 
SC
A
N
 –
 S
te
p
w
is
e 
st
ra
te
gy
 t
o
 im
p
ro
ve
 c
er
vi
ca
l c
an
ce
r 
sc
re
en
in
g 
ad
h
er
en
ce
. S
M
S 
– 
sh
o
rt
 m
e
ss
ag
e 
se
rv
ic
e 
te
xt
 m
e
ss
ag
e.
  
*T
h
e 
st
an
d
ar
d
 o
f 
ca
re
 s
tr
at
eg
y 
o
f 
w
o
m
en
 in
vi
ta
ti
o
n
 t
o
 c
er
vi
ca
l c
an
ce
r 
sc
re
en
in
g 
is
 d
ep
ic
te
d
 in
 d
ar
k 
gr
ey
. T
h
e 
st
ra
te
gi
es
 r
e
p
re
se
n
te
d
 in
 p
in
k 
w
er
e 
te
st
ed
 a
s 
in
te
rv
e
n
ti
o
n
s 
in
 
SC
A
N
-C
er
vi
ca
l C
an
ce
r 
tr
ia
l. 
O
ra
n
ge
 c
ir
cl
es
 r
ep
re
se
n
t 
th
e 
ti
m
ep
o
in
ts
 c
o
n
si
d
er
ed
 f
o
r 
th
e 
o
u
tc
o
m
e 
as
se
ss
m
en
t 
in
 t
h
e 
SC
A
N
-C
er
vi
ca
l C
an
ce
r 
tr
ia
l. 
B
o
ld
 f
ig
u
re
s 
re
p
re
se
n
t 
th
e 
o
b
se
rv
ed
 a
d
h
er
en
ce
 p
ro
p
o
rt
io
n
s 
to
 c
er
vi
ca
l c
an
ce
r 
sc
re
en
in
g.
 F
o
r 
in
te
rv
en
ti
o
n
s 
(b
) 
an
d
 (
c)
 t
h
e 
ad
h
er
en
ce
 t
o
 c
er
vi
ca
l c
an
ce
r 
sc
re
en
in
g 
w
as
 d
et
er
m
in
ed
 o
n
 S
C
A
N
-C
er
vi
ca
l 
C
an
ce
r 
tr
ia
l 4
5
 a
n
d
 9
0
 d
ay
s 
af
te
r 
th
e 
in
it
ia
l i
n
vi
ta
ti
o
n
, r
e
sp
ec
ti
ve
ly
. 
Th
e
re
fo
re
, t
o
 e
n
su
re
 a
n
 a
cc
u
ra
te
 c
o
m
p
ar
is
o
n
 b
et
w
ee
n
 s
tr
at
eg
ie
s 
(a
),
 (
b
),
 (
c)
 a
n
d
 (
d
),
 t
h
e 
ad
h
er
en
ce
 t
o
 
ce
rv
ic
al
 c
an
ce
r 
sc
re
en
in
g 
sh
o
u
ld
 h
av
e 
b
ee
n
 d
et
er
m
in
ed
 i
n
 t
h
e 
sa
m
e 
ti
m
ep
o
in
t 
(i
.e
.,
 1
5
0
 d
ay
s 
af
te
r 
th
e 
in
it
ia
l 
in
vi
ta
ti
o
n
).
 H
o
w
ev
er
, 
th
e 
SC
A
N
-C
er
vi
ca
l 
C
an
ce
r 
tr
ia
l 
o
n
ly
 
as
se
ss
ed
 t
h
e 
o
u
tc
o
m
e 
at
 t
h
is
 t
im
ep
o
in
t 
fo
r 
st
ra
te
gy
 (
a)
 a
n
d
 (
d
).
 F
o
r 
th
e 
re
m
ai
n
in
g 
st
ra
te
gi
es
, w
e 
ex
p
ec
t 
th
at
 w
o
m
en
 m
ay
 b
e 
o
p
p
o
rt
u
n
is
ti
ca
lly
 in
vi
te
d
 b
y 
th
ei
r 
fa
m
ily
 d
o
ct
o
rs
 
to
 s
cr
ee
n
in
g 
d
u
ri
n
g 
ap
p
o
in
tm
e
n
ts
 s
ch
ed
u
le
d
 f
o
r 
o
th
er
 h
ea
lt
h
 p
u
rp
o
se
s,
 in
cr
ea
si
n
g 
th
e 
ad
h
er
e
n
ce
 t
o
 s
cr
ee
n
in
g.
 T
o
 c
o
n
si
d
er
 t
h
e 
p
o
ss
ib
le
 e
ff
ec
t 
o
f 
o
p
p
o
rt
u
n
is
ti
c 
in
vi
ta
ti
o
n
s 
af
te
r 
st
ra
te
gi
e
s 
(b
) 
an
d
 (
c)
, 
an
 e
xp
ec
te
d
 i
n
cr
ea
se
 i
n
 a
d
h
er
en
ce
 o
f 
4
%
 a
n
d
 2
%
 w
as
 a
p
p
lie
d
, 
re
sp
ec
ti
ve
ly
; 
th
e 
co
rr
ec
te
d
 a
d
h
er
e
n
ce
 e
st
im
at
es
 a
ft
er
 s
tr
at
e
gy
 (
b
) 
an
d
 (
c)
 a
re
 
d
ep
ic
te
d
 in
 d
ar
k 
b
lu
e.
 †
Th
is
 p
ar
am
et
er
 w
as
 v
ar
ie
d
 in
 t
h
e 
se
n
si
ti
vi
ty
 a
n
al
ys
is
 b
et
w
ee
n
 0
 a
n
d
 8
.8
%
 (
p
le
as
e 
se
e 
Ta
b
le
 3
 f
o
r 
fu
rt
h
er
 d
et
ai
ls
).
 †
†T
h
is
 p
ar
am
et
e
r 
w
as
 v
ar
ie
d
 in
 t
h
e
 
se
n
si
ti
vi
ty
 a
n
al
ys
is
 b
et
w
ee
n
 0
 a
n
d
 3
.3
%
 (
p
le
as
e 
se
e 
Ta
b
le
 3
 f
o
r 
fu
rt
h
e
r 
d
et
ai
ls
) 
A
p
p
e
n
d
ix
 1
 –
 D
e
sc
ri
p
ti
o
n
 o
f 
th
e
 c
o
m
p
e
ti
n
g 
in
te
rv
e
n
ti
o
n
s 
te
st
e
d
 in
 t
h
e
 S
C
A
N
-C
e
rv
ic
a
l 
C
an
ce
r 
Tr
ia
l*
  
Papers | 108 
 
Appendix 2 - Detailed description of the transition probabilities for each invitation strategy* 
 
SMS - short message service text message. *All probabilities presented were obtained from the Stepwise strategy to improve cervical 
cancer screening adherence (SCAN-Cervical Cancer trial). 
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Appendix 3 - Cost calculation details for the competing interventions. 
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SMS - short message service text messages. *Health care professionals’ time consumption per procedure was determined by direct 
observation of health professionals of two (randomly selected) primary care units. An average time was calculated by taking the 
mean time of five of the same procedures performed by three different health professionals in both primary care units. We used 
Portuguese Health Ministry public sources to derive salary costs.1,2 †A wage of 1300€/month was considered, based on the regular 
salary of a clinical secretary salary and a 25% increase to consider the production incentives usually applied in Portuguese Primary 
Care Units.1 ††Unit costs of the invitation method and software were obtained from a standard private provider. ¶A wage of 
1800€/month was considered based on the publicly available data from the Portuguese health costs center (Administração Central 
dos Serviços de Saúde).2 §Costs due to work time lost were determined by multiplying the number of hours lost due to treatments 
by the Portuguese minimum wage salary (557€ per month), which corresponds to 3.48€ per hour.3 Opportunity costs were fixed at 
6.96€ per visit (with an estimated two hours of time spent per visit) and travel costs at 3.48€.      
References: 
1 - Source: Legal document - Portaria n. º 1553-C/2008, published on 31st December of 2008, by the Presidência do 
Conselho de Ministros e Ministério das Finanças.  
2 - Source: Tabela Salarial 2014. Retrieved from http://www2.acss.min-
saude.pt/portals/0/Tabela%20remunerat%C3%B3ria_rev_101215.pdf. Accessed on 01/03/2018.  
3 - Source: PORDATA (portuguese statistics website). Retrieved from http://www.pordata.pt/Europa/PIB+per+capita+(PPS)-
1778. Accessed on 01/09/2017.      
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4 | GENERAL DISCUSSION AND CONCLUSIONS 
This thesis used a methodologically robust randomized controlled trial to show that a stepwise 
strategy of invitation to cervical cancer screening, based on automated text messages/phone 
calls/reminders (step 1), manual phone calls (step 2) and face-to-face interviews (step 3), as well 
as invitation strategies based on step 1 or steps 1+2, were significantly more effective than the 
standard of care (Papers I, II, IV).  
The implementation of the proposed invitation strategies at a population level requires solid 
evidence regarding their effectiveness, but also on their cost-effectiveness, which was analyzed 
in Paper V. This study showed that an invitation to cervical cancer screening based on steps 1+2 
was very cost-effective, both from the societal and provider perspectives, surpassing the 
standard of care, as well as the interventions based on step 1 or steps 1+2+3, when the 
willingness-to-pay threshold is defined at one time the Portuguese gross domestic product per 
capita. 
This thesis adds to previous research on strategies to increase adherence to cervical cancer 
screening an essentially pragmatic and population-based assessment of a stepwise intervention, 
with a clear gradient of customization and cost, combining easy-to-implement strategies with 
highly customized interventions. This was also one of the few investigations supporting the 
implementation of a new invitation strategy for organized cervical cancer screening with a 
detailed cost-effectiveness analysis that considers high quality patient-level data. The major 
limitations of the previously published articles on this topic91,94,95,97,103,106, were surpassed by our 
study that considered QALYs as the outcome of the cost-effectiveness models and not only 
adherence to cervical cancer screening, but also through the quantification of costs and benefits 
both from the provider and societal perspective.  
Some overall limitations should be addressed regarding the studies conducted. Although women 
aged 25 to 65 years are considered eligible for cervical cancer screening, the SCAN trial only 
included those below 50 years of age, who use their mobile phones more often and benefit the 
most from the proposed interventions.108 Therefore, the conclusions of this thesis may not apply 
to older women, who may have different digital skills, despite most of Portuguese women, aged 
50 years or above, already use their mobile phone on a daily basis.108 Additionally, the proposed 
multistep intervention considered automated strategies, but also manual phone calls and face-
to-face interviews which are expected to be easily accepted by women with less digital literacy.  
Women with no available mobile phone registered in the National Health Service database were 
considered not eligible, since the tested interventions require a functional mobile phone 
number to be delivered. However, since less than 3% of the potentially eligible women were 
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excluded before randomization due to this criterion, this is expected to have a limited impact on 
the conclusions drawn in Papers II and IV. Regarding women randomized to the intervention 
group, a large proportion had an invalid mobile phone number, precluding the delivery of the 
tested strategies, reducing their effectiveness. However, due to the ongoing improvement of 
mobile phone number records in Portugal, the effect of the tested interventions is expected to 
increase, potentially reaching the values calculated in the per-protocol analyses.109  
Approximately 50% of the invited primary health care units refused to participate in the current 
trial and among those who were enrolled in the study, around 20% did not apply step 3 
intervention. This may be explained because the medical doctors of the primary health care 
units have limited time available in their clinical schedule to implement the face-to-face 
interviews (step 3 intervention). However, this is not expected to limit the regular use of an 
intervention based on steps 1+2 (i.e., the most cost-effective invitation strategy), since it is based 
on automated text messages/phone calls/reminders and manual phone calls, that do not require 
the direct participation of medical doctors to be implemented. Additionally, if step 1+2 
intervention is defined as the standard of care invitation to cervical cancer screening, it is 
anticipated that the Ministry of Health will define time periods in the clinical secretaries’ 
schedules just to perform manual phone calls, contributing for a higher adoption of this strategy.  
Considering the previous arguments, a higher adoption of step 1+2 intervention is expected to 
occur if it is implemented at a national level, increasing the effectiveness of this strategy and 
contributing to reduce the difference between the computed intention-to-treat and per-
protocol effect estimates. Contamination may have occurred, because women can undergo 
screening for free and the participants randomized to the intervention group may live 
geographically near to those in the control group. However, if contamination has occurred, it 
would reduce the difference between groups, resulting in conservative effect estimates.  
The conducted cost-effectiveness analysis considered a 5-year time-frame, which has the 
advantage of using reliable parameters, namely survival estimates, that are usually calculated 
five years after the diagnosis of a cervical cancer or a pre-malignant disease. A life-time 
perspective could have been used instead, including longer-term benefits, that are expected to 
occur due to a carryover effect of the intervention, resulting in lower cost-effectiveness ratios. 
However, this approach would require the use of life-time costs and survival parameters in the 
decision tree model, which are often imprecise and difficult to estimate. Additionally, a 
sensitivity analysis showed that the invitation based on steps 1+2 is expected to remain the most 
cost-effective strategy, even if the number of QALYs of all the tested interventions increases 
10% (analysis not presented in Paper V). 
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The evidence produced with this thesis was disseminated through academic publications and 
presentations in scientific conferences. Study findings were also communicated to the involved 
primary health care units and professionals through face-to-face meetings, with the support of 
customized reports, which were assembled using the two-page template proposed in Paper III. 
The conclusions of this work were presented to the coordinators of the organized screening 
programs of the North and Lisbon Health Regions of Portugal (Administração Regional de Saúde 
do Norte and Administração Regional de Saúde de Lisboa e Vale do Tejo). All these 
communication strategies were used to promote the adoption of automated text 
messages/phone calls/reminders and manual phone calls as the new invitation method for 
cervical cancer screening, since this strategy is more effective and cost-effective than the 
standard of care.  
In conclusion, the results of this thesis support the implementation of automated text 
messages/phone calls/reminders and manual phone calls as the new standard of care invitation 
to cervical cancer screening, under a willingness-to-pay threshold of one time the Portuguese 
gross domestic product per capita. The implementation of this strategy may be expected to 
increase the cost-effectiveness of organized screening and have a positive impact on the 
population’s health.  
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